Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7070179 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| RO7070179 | EXPERIMENTAL | Participants will receive RO7070179, 13 mg/kg/week, 2-hour IV infusion every week in a 6-week cycle, after two loading doses in Week 1 of Cycle 1 on Day 1 and Day 4. If a dose-limiting toxicity (DLT) occurs in more than 33% of participants at any time, the dose will be reduced to 10 mg/kg/week. The dose will be further reduced to 6 mg/kg/week if more than 33% of treated participants have a DLT. |
| Name | Type | Description |
|---|---|---|
| RO7070179 | DRUG | RO7070179 (13 mg/kg/week) will be administered as 2-hour IV infusion. |
Inclusion Criteria: * Male or female of \>=18 years of age with the Eastern Cooperative Oncology Group (ECOG) performance status 0-1, Child-Pugh score of 5-7, and Life expectancy of 3 months or greater. * Confirmed to have HCC as described by the American Association for the Study of Liver Disease ...
RO7070179 is an investigational small molecule being studied for the treatment of hepatocellular carcinoma (HCC), a type of liver cancer. It is designed to target HIF1A messenger ribonucleic acid (mRNA) as an antagonist, with the goal of demonstrating proof-of-mechanism in adult patients with HCC.
RO7070179 targets hypoxia-inducible factor 1a (HIF1A) messenger ribonucleic acid (mRNA). It acts as an antagonist to HIF1A mRNA, which is a key factor in cellular response to low oxygen conditions and is often implicated in tumor growth and progression.
RO7070179 is being developed by Roche Holding AG, a multinational healthcare company. Roche is conducting clinical research on this investigational drug for hepatocellular carcinoma, and the company is publicly traded under the ticker RHHBY.
RO7070179 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials to evaluate its safety, tolerability, and mechanism of action in patients.
RO7070179 has been studied in one completed Phase 1 clinical trial, identified as NCT02564614. This trial was an uncontrolled, non-randomized study conducted in the United States, enrolling 9 adult participants with hepatocellular carcinoma to evaluate the drug's proof-of-mechanism.
RO7070179 is a hypoxia-inducible factor 1a (HIF1A) messenger ribonucleic acid (mRNA) antagonist. The drug is designed to inhibit HIF1A mRNA, and it is being investigated for its potential role in treating hepatocellular carcinoma by targeting this specific molecular pathway.